

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
1107-3 DIV

SERIAL NO.
10/601,940

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT
Sosnowski, et al.

CUSTOMER NO.
33769

(Use several sheets if necessary)

FILING DATE
June 23, 2003

GROUP ART UNIT
Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
AC	—	5,866,585	2/2/99	Fogel			
AC	—	6,054,128	4/25/00	Wakat			
AC	—	5,922,773	7/13/99	Lipton et al.			
AC	—	6,025,369	2/15/00	Rosenquist et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
AC	—	WO 00/37087 A1	6/29/00	PCT				


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AC	—	Bucci, L.R., FDA filing reference, August 27, 1999, pp. 1 and 2.
AC	—	Pei I. Ho et al., <i>Multiple Aspects of Homocysteine Neurotoxicity: Glutamate Excitotoxicity, Kinase Hyperactivation and DNA Damage</i> , Journal of Neuroscience Research 70:694-702 (December, 2002).

EXAMINER /Abigail Cotton/ (06/28/2006) DATE CONSIDERED 06/28/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 (Rev. 2-32) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 1107-3 DIV	SERIAL NO. 10/601,940
	APPLICANT Sosnowski, et al.	CUSTOMER NO. 33769
	FILING DATE June 23, 2003	GROUP ART UNIT Unassigned



AC	<input checked="" type="checkbox"/>	Seshadri, S. et al., <i>Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease</i> , 1: N Engl J Med. 2002 Feb 14; 346(7):476-83.
AC	<input checked="" type="checkbox"/>	Fonseca, V.A. et al., <i>Insulin Sensitivity and Plasma Homocysteine Concentrations in Non-Diabetic Obese and Normal Weight Subjects</i> , Atherosclerosis, 2003 March; 167(1):105-9.
*	<input checked="" type="checkbox"/>	A. Ambrosch et al., <i>Relation Between Homocysteinaemia and Diabetic Neuropathy in Patients with Type 2 Diabetes</i> , Diabetic Medicine, Volume 18, Issue 3, p.185, March 2001.
AC	<input checked="" type="checkbox"/>	Pamela Moore et al., <i>Apoptotic Cell Death in the Mouse Retinal Ganglion Cell Layer is Induced in Vivo by the Excitatory Amino Acid Homocysteine</i> , Exp Eye Res. 73(1), pp. 45-57, July, 2001, Academic Press.
AC	<input checked="" type="checkbox"/>	Centrum references, Whitehall Robins: <i>Centrum Focused Formulas Heart and Centrum Herbals Ginkgo</i> , from www.centrum.com.
AC	<input checked="" type="checkbox"/>	McCully, Kilmer S., M.D., <i>The Homocysteine Revolution "A Bold New Approach to the Prevention of Heart Disease"</i> , Keats Publishing, Los Angeles 1997, pp. 33, 64-65, 92-105, 137, 181.
AC	<input checked="" type="checkbox"/>	Bleich S., Degner, D., Bandelow, B., von Ahsen, N., Ruther, E., Kornhuber, J., <i>Plasma Homocysteine is a Predictor of Alcohol Withdrawal Seizures</i> , Neuroreport 2000, Aug. 21 Abstract.

* This reference has not been considered because no copy has been provided by Applicants.

EXAMINER /Abigail Cotton/ (DATE CONSIDERED 06/28/2006)

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.